Leqembi Global Rollout Eisai US is driving international expansion of Leqembi with launches in Austria and China in 2024, including deliveries to the private market. This signals growing demand for Alzheimer’s therapies and creates opportunities for regional distributors, specialty pharmacies, and payer negotiations to secure access and reimbursement.

Academic Collaboration Eisai is pursuing tau targeting research with leading academic centers, notably a collaboration with University College London on etalanetug (E2814). This opens doors for co development opportunities, investigator initiated trials, and site networks you can engage for clinical programs and supply partnerships.

Patient Access The LEQEMBI Companion program demonstrates Eisai’s focus on patient support and adherence. Sales opportunities exist in payer engagement, patient assistance services, and partnerships with patient organizations or digital health tools that facilitate access to therapy.

Neurology Leadership With two end to end global business groups focused on oncology and neurology, Eisai offers a comprehensive neurology portfolio from discovery to marketing. This setup creates openings to partner with neurology clinics, memory care centers, and academic hospitals for trials, real world evidence programs, and pharmacovigilance collaborations.

Global Supply and Access As a US subsidiary of a fully integrated global pharma business, Eisai US can leverage coordinated supply chain and market access activities for cross border opportunities in Europe and Asia, including distribution partnerships, co marketing arrangements, and regulatory collaborations.